Streetbeat News

Regulatory

NVO

Novo Nordisk announced the upcoming presentation of new data on cardiometabolic diseases at the American Heart Association's annual Scientific Sessions. The data includes results from the SELECT and STEP HFpEF phase 3 trials on obesity and cardiovascular disease, and the AWARE study on treatment gaps in adults with type 2 diabetes. The company emphasized its commitment to addressing unmet needs in cardiometabolic diseases and its progress in research that could inform treatment decisions.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:44 pm

CZR

ELYS

Elys Game Technology has announced a market access agreement with Caesars Entertainment, marking its first entry into the North American mobile sports betting market. The agreement allows Elys to launch its online sportsbook operations in Colorado, subject to regulatory approvals. The company plans to expand its market position by offering its new '5D by Elys' mobile app to sports bettors across multiple states through future market access partnerships.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:40 pm

AMKR

Amkor Technology, Inc. (NASDAQ:AMKR) has committed to setting targets to reduce greenhouse gas emissions in alignment with the Science Based Targets initiative (SBTi). The company's commitment includes the formulation of both near-term and net zero emissions targets. Amkor plans to submit its targets to SBTi for validation in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:39 pm

BCAN

BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) announced a new plan of work focusing on its proprietary CRM platform to meet the increased demand for medical cannabis in Israel. This follows recent regulatory reforms allowing cannabis as a first-line treatment, leading to a surge in licensed medical cannabis patients. The company's Benefit CRM helps optimize functions like sales management and asset management. The software development phase will focus on AI elements to increase data collection and analysis. In February 2023, BYND Cannasoft received a full license to trade in medical cannabis products.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:34 pm

QLGN

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) has announced the first patient dosing in the Phase 1a clinical trial of QN-302, a potential treatment for advanced or metastatic solid tumors. The trial is being conducted at START Midwest in Grand Rapids, Michigan. QN-302, a G-Quadruplex (G4)-selective transcription inhibitor, was licensed by Qualigen in January 2021 and received Orphan Drug Designation for the treatment of pancreatic cancer. The company expects to provide an update on the trial's safety and preliminary efficacy in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:33 pm

BEAT

HeartBeam has been granted a US patent for a 12-lead extended wear patch for detecting heart attacks and complex cardiac arrhythmias. The company's stock, BEAT, may be impacted by this news.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:32 pm

SLRX

Salarius Pharmaceuticals has completed an FDA Type B meeting for its Seclidemstat Ewing Sarcoma development program. The meeting is a significant step in the drug's development process.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:30 pm

SPY

The US trade balance for September was reported at $(61.5B), worse than the estimated $(59.9B).

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:30 pm

GE

General Electric Co (NYSE:GE) has agreed to a $9.4 million settlement with the U.S. Department of Justice over claims that its GE Aerospace's Lynn facility sold improperly inspected or noncompliant parts to the U.S. Army and Navy. The settlement covers a period from July 2014 to December 2019. GE Aerospace has taken corrective steps to prevent future occurrences. GE is in the process of segregating into three entities focusing on aviation, energy, and healthcare.

Portfolio Pulse from Shivani Kumaresan

November 07, 2023 | 1:26 pm

SPY

Federal Reserve's Goolsbee has indicated that the current trends are expected to continue. No specific details or changes were mentioned.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:18 pm